{
    "clinical_study": {
        "@rank": "100791", 
        "arm_group": {
            "arm_group_label": "ICOVIR5", 
            "arm_group_type": "Experimental", 
            "description": "ICOVIR-5 oncolytic adenovirus, single administration, endovenous, dose escalation from 1E11 vp to 1E13 vp."
        }, 
        "brief_summary": {
            "textblock": "The investigators will evaluate the safety of a single endovenous infusion of ICOVIR5 in\n      adults with locally advanced and metastatic melanoma. ICOVIR5 consists in a conditionally\n      replicative or oncolytic adenovirus."
        }, 
        "brief_title": "Phase I Endovenous Administration of Oncolytic Adenovirus ICOVIR-5 in Patients With Advanced or Metastatic Melanoma", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Locally Advanced or Metastatic Melanoma", 
        "condition_browse": {
            "mesh_term": [
                "Adenoviridae Infections", 
                "Melanoma"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Malignant melanoma advanced or metastatic.\n\n          -  Other than 18 years\n\n          -  Karnofsky index > 60 %\n\n          -  Life expectancy > 3 months\n\n          -  ALT/AST <=2.5 times the upper normal limit\n\n          -  Creatinine clearance >= 50 ml/min.\n\n          -  Bilirubin <25 umol/l\n\n          -  Alkaline phosphatase <= 2.5 time upper normal limit\n\n          -  Normal bone marrow function: Neutrophils >=1.5 E9/L, platelets >= 1E11/L, hemoglobin\n             >= 100 g/l, Normal prothrombin time and thromboplastin time,\n\n          -  HIV negative\n\n          -  Measurable disease\n\n          -  Signed informed consent.\n\n        Exclusion Criteria:\n\n          -  Geographical, social or psychological conditions that may impair the protocol\n             compliance.\n\n          -  Active infections or other severe medical status.\n\n          -  History of liver disease.\n\n          -  Other or concomitant treatments for melanoma or investigational product.\n\n          -  Previous participation in studies with adenovirus.\n\n          -  Virus diseases diagnosed two weeks before inclusion.\n\n          -  Immunosuppressive concomitant treatments\n\n          -  Concomitant malignant haematological disease.\n\n          -  Patients having family members with immunodeficient status or disease\n\n          -  Patients with Li Fraumeni syndrome or germinal retinoblastoma gene defects."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "15", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01864759", 
            "org_study_id": "ICOVIR5-2", 
            "secondary_id": "2008-005694-35"
        }, 
        "intervention": {
            "arm_group_label": "ICOVIR5", 
            "intervention_name": "ICOVIR-5", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "melanoma", 
            "oncolytic", 
            "adenovirus", 
            "virotherapy", 
            "locally advanced", 
            "metastatic"
        ], 
        "lastchanged_date": "January 14, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "L'Hospitalet del Llobregat", 
                    "country": "Spain", 
                    "state": "Barcelona", 
                    "zip": "08908"
                }, 
                "name": "Institut Catal\u00e0 d'Oncologia - L'Hospitalet"
            }, 
            "investigator": [
                {
                    "last_name": "Ram\u00f3n Salazar, MD PhD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Marta Gil, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Maria Ochoa de Olza, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase I Clinical Trial of Endovenous Administration of Conditionally Replicative Adenovirus ICOVIR-5 in Patients With Locally Advanced or Metastatic Melanoma", 
        "other_outcome": [
            {
                "description": "Viremia at 0 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours and 24 hours after endovenous injection.", 
                "measure": "Viral pharmacokinetics", 
                "safety_issue": "No", 
                "time_frame": "1 day"
            }, 
            {
                "description": "Virus presence in tumors at day 5 post-administration.", 
                "measure": "Viral pharmacodynamics", 
                "safety_issue": "No", 
                "time_frame": "5 days"
            }
        ], 
        "overall_contact": {
            "email": "ramonsalazar@iconcologia.net", 
            "last_name": "Ramon Salazar, MD PhD", 
            "phone": "34.93.260.77.44"
        }, 
        "overall_contact_backup": {
            "email": "mgilmartin@iconcologia.net", 
            "last_name": "Marta Gil, MD", 
            "phone": "34.93.260.77.44"
        }, 
        "overall_official": [
            {
                "affiliation": "Institut Catala D'Oncologia", 
                "last_name": "Ramon Salazar, MD PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Institut Catal\u00e0 d'Oncologia", 
                "last_name": "Ramon Alemany, PhD", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The highest dose where less than two out of three or six patients suffered dose limiting toxicity.", 
            "measure": "Maximum tolerated dose", 
            "safety_issue": "Yes", 
            "time_frame": "4 weeks"
        }, 
        "reference": {
            "PMID": "17579575", 
            "citation": "Cascallo M, Alonso MM, Rojas JJ, Perez-Gimenez A, Fueyo J, Alemany R. Systemic toxicity-efficacy profile of ICOVIR-5, a potent and selective oncolytic adenovirus based on the pRB pathway. Mol Ther. 2007 Sep;15(9):1607-15. Epub 2007 Jun 19."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01864759"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Recommended dose", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }, 
            {
                "measure": "Anti-tumour activity", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }
        ], 
        "source": "Institut Catal\u00e0 d'Oncologia", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Institut Catal\u00e0 d'Oncologia", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}